Ascendis Pharma A/S

Equities

ASND

US04351P1012

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 01:29:35 2024-04-25 pm EDT			5-day change	1st Jan Change
136.8 ^USD	-4.49%		-2.41%	+9.17%

05:11pm	European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading	MT
Apr. 24	Ascendis Pharma Gets UK Regulator's Approval for Yorvipath to Treat Hypoparathyroidism	MT

Ascendis Pharma A/S Appoints William Carl Fairey Jr. and Siham Imani as Class I Directors

September 12, 2022 at 04:07 pm EDT

Ascendis Pharma A/S appointed William Carl Fairey Jr. and Siham Imani as Class I directors, with the term for such board members to expire at the Annual General Meeting of the Company to be held in 2023.

Latest news about Ascendis Pharma A/S

European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading	11:11am	MT
Ascendis Pharma Gets UK Regulator's Approval for Yorvipath to Treat Hypoparathyroidism	Apr. 24	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down	Apr. 19	MT
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading	Apr. 18	MT
JPMorgan Adjusts Ascendis Pharma A/S Price Target to $167 From $165, Maintains Overweight Rating	Apr. 02	MT
European Equities Traded in the US as American Depositary Receipts Slightly Higher Thursday	Mar. 28	MT
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	Mar. 21	MT
Wells Fargo Raises Ascendis Pharma Price Target to $260 From $196, Maintains Overweight Rating	Mar. 15	MT
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Wednesday Trading	Mar. 13	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading	Mar. 12	MT
Ascendis Pharma A/S Appoints Mads Bodenhoff as Senior Vice President, Finance Principal Accounting Officer	Feb. 29	CI
European Equities Traded in the US as American Depositary Receipts Set to End Week Higher in Friday Trading	Feb. 16	MT
European Equities Traded in US as American Depositary Receipts Move Slightly Higher in Friday Trading	Feb. 09	MT
Citigroup Raises Price Target on Ascendis Pharma to $182 From $146, Maintains Buy Rating	Feb. 08	MT
Wedbush Raises Ascendis Pharma's Pt to $225 From $207, Notes Multiple Catalysts Across Pipeline in Q4 2024; Keeps Outperform Rating	Feb. 08	MT
Ascendis Pharma Q4 Net Loss Narrows, Revenue Rises	Feb. 07	MT
Transcript : Ascendis Pharma A/S, 2023 Earnings Call, Feb 07, 2024	Feb. 07
Earnings Flash (ASND) ASCENDIS PHARMA Posts Q4 Revenue EUR137.7M	Feb. 07	MT
Ascendis Pharma A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 07	CI
Ascendis Pharma A/S Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 07	CI
Cantor Fitzgerald Adjusts Price Target on Ascendis Pharma to $173 From $152, Keeps Overweight Rating	Feb. 06	MT
European Equities Traded in the US as American Depositary Receipts Make Modest Gains in Thursday Trading	Feb. 01	MT
Ascendis Pharma A/S Launches 2nd TransCon Product: YORVIPATH Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism	Jan. 31	CI
European Equities Traded in the US as American Depositary Receipts Move Lower in Tuesday Trading	Jan. 30	MT
Ascendis Spinning Off Ophthalmology Assets into Eyconis with Venture Firms Backing	Jan. 29	MT

Chart Ascendis Pharma A/S

Duration

Period

More charts

Company Profile

Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).

Sector

Biotechnology & Medical Research

Calendar

2024-05-21 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Ascendis Pharma A/S

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

134 EUR

Average target price

166.7 EUR

Spread / Average Target

+24.43%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ASCENDIS PHARMA A/S	+9.17%	8.18B
VERTEX PHARMACEUTICALS INCORPORATED	-2.14%	104B
REGENERON PHARMACEUTICALS, INC.	+1.83%	97.42B
ARGENX SE	+0.79%	22.2B
BIONTECH SE	-17.81%	21.23B
GENMAB A/S	-11.11%	18.33B
WUXI APPTEC CO., LTD.	-42.83%	16.35B
BEIGENE, LTD.	-16.41%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+3.67%	13.98B
SAREPTA THERAPEUTICS, INC.	+35.20%	11.66B

Bio Therapeutic Drugs